Consulting Women's Health

Advancing Women’s Health Through Model-Informed Drug Development 

Advancing Women’s Health Through Model-Informed Drug Development 
Last Updated: November 18, 2026, 1 pm UTC

Women’s health clinical development must account for biological variables that can change within and across patient populations. Hormonal fluctuations, reproductive stage, contraceptive use, and differences in physiology may influence drug exposure, treatment response, and safety. Yet when development decisions rely heavily on population averages, important sources of variability may not be fully considered until clinical studies are underway. 

The consequences extend beyond the scientific design of a trial. Decisions about dosing, endpoints, and assessments influence which patients can participate, what sites must be equipped to deliver, and what evidence will ultimately support regulatory discussions. Addressing these questions late can introduce unnecessary complexity into an already demanding development process. 

Model-informed drug development (MIDD) offers sponsors a way to evaluate these considerations earlier. By integrating biological, pharmacological, and clinical data into quantitative models and simulations, development teams can better understand uncertainty and use that evidence to inform connected decisions across the program. 

Accounting for Biological Variability Earlier in Development 

MIDD draws on complementary modeling approaches to characterize how a treatment may behave in different physiological conditions. Physiologically based pharmacokinetic (PBPK) modeling examines drug disposition in relation to organ function and physiology. Population pharmacokinetic/pharmacodynamic (PK/PD) models characterize variability in exposure and response. Quantitative systems pharmacology (QSP) models connect disease biology, drug mechanisms, and potential treatment effects. 

These approaches are particularly relevant when physiological changes complicate conventional assumptions about exposure or dosing. In fertility development, for example, population PK/PD and biomarker models can incorporate anti-Müllerian hormone, antral follicle count, and estradiol dynamics to evaluate gonadotropin dosing strategies. Such analyses can help teams examine the balance between adequate ovarian response and the risk of ovarian hyperstimulation. 

Pregnancy presents a different set of questions. Changes in blood volume, renal function, and metabolic enzyme activity may alter drug disposition as gestation progresses. Pregnancy-specific PBPK models can simulate these changes and explore potential implications for maternal exposure, placental transfer, and dosing strategies where clinical data are limited. 

In MIDD for women’s health, accounting for fluctuating estrogen levels is critical because estrogen directly regulates key drug-metabolizing enzymes, such as CYP1A2, CYP2C19, CYP3A4, and UGT1A4. Both natural endogenous shifts—across the menstrual cycle, pregnancy, and menopause—and exogenous therapies like oral contraceptives or hormone replacement can significantly alter how quickly medications are cleared from the body. For example, high estrogen states can slow down the metabolism of certain drugs, increasing exposure and side-effect risks, while simultaneously accelerating the clearance of others and reducing their effectiveness. By integrating these dynamic hormonal states and administration routes into pharmacokinetic models, MIDD helps researchers predict sex-specific drug responses and tailor safer, more effective dosing regimens for women across every life stage. 

These applications illustrate how modeling can complement clinical evidence by identifying plausible sources of variability, testing assumptions, and informing the questions that warrant further investigation. These insights can then guide the design of more informative clinical studies. 

Translating Model-Informed Evidence Into Better Study Design 

The influence of MIDD extends across several critical study design decisions. Simulations can support dose selection, endpoint development, biomarker selection, PK/PD sampling, and visit timing. Identifying when a measurement is likely to be most informative may help teams design assessment schedules that capture meaningful data while limiting procedures that contribute little scientific value. 

Modeling can also strengthen the statistical assumptions underpinning trial design. By combining model-informed estimates with findings from previous studies, biostatisticians can evaluate expected treatment effects and variability more rigorously when determining sample size. This is particularly consequential in Phase 3 development, where sample size affects the likelihood of detecting a treatment effect, if one exists, as well as enrollment requirements, timelines, and cost. 

Importantly, these decisions are interdependent. Changing a dose, population definition, or assessment schedule may affect the data a study can generate and the resources needed to execute it. Evaluating alternative scenarios before protocol finalization gives sponsors a stronger basis for selecting a design that is scientifically justified and operationally achievable. 

Strengthening Feasibility and Trial Execution 

Once modeling has clarified which patient characteristics matter most to exposure, response, or safety, those insights can improve feasibility planning. In women’s health, factors such as menopausal status, cycle phase, hormone therapy, contraceptive use, and biomarker profiles can substantially affect who qualifies for a study. Understanding their relevance can help sponsors refine eligibility criteria, minimize unnecessary restrictions, and maintain appropriate safety safeguards. 

That precision carries into site selection. Feasibility teams can move beyond broad indication-level prevalence estimates to assess whether sites have access to the specific patient population required and the capabilities to support the protocol. Depending on the study, those capabilities may include hormonal assessments, specialized imaging, reproductive endocrinology expertise, or timed pharmacokinetic sampling. 

The same evidence can help reduce patient and site burden. Cycle-timed visits, repeated blood draws, pregnancy testing, diaries, and frequent assessments can make participation difficult. When modeling identifies the sampling windows and procedures most likely to generate useful information, teams can evaluate opportunities to streamline assessments while preserving scientific rigor. 

More realistic eligibility and assessment requirements can, in turn, improve assumptions about screen failures, recruitment rates, site capacity, and country mix. Greater confidence in dose and patient-response relationships may also lower the likelihood of adding cohorts or making substantial protocol changes after a trial begins. Avoiding those changes can limit operational disruption associated with retraining, regulatory and ethics submissions, reconsenting, and data system updates. 

Together, these refinements support a development plan grounded in biological evidence and the practical circumstances of the patients and sites expected to participate. The resulting efficiencies can have meaningful implications for study timelines, costs, and execution quality. 

Building Regulatory Confidence Through Early Alignment 

Model-informed strategies also need to be considered in the context of the evidence regulators will evaluate. The relevant question is not whether a model is sophisticated, but whether it is suitable for a defined decision. Sponsors should establish its intended context of use, the data and assumptions supporting it, and the uncertainties that remain. 

Engagement with FDA can begin early, including during investigational new drug development where appropriate. Depending on the question, sponsors may introduce modeling considerations in conventional regulatory interactions or explore a dedicated MIDD discussion. Clearly articulating how the analysis informs dose selection, study design, or another development decision helps make that dialogue more focused and productive. 

Incorporating regulatory expertise early can also help teams identify where additional validation or clinical evidence may be needed to support consequential decisions. This alignment strengthens the connection between modeling objectives, development strategy, and the evidence sponsors will ultimately need to generate. 

Bringing the Disciplines Together 

Realizing the full potential of MIDD in women’s health requires coordinated expertise across the development program. Pharmacometrics can illuminate biological and pharmacological variability; biostatistics can translate that evidence into study assumptions; clinical operations can evaluate the feasibility of the resulting design; and regulatory strategy can help establish how the evidence supports development objectives. 

When these perspectives inform one another early, sponsors are better positioned to design studies that reflect the populations they intend to serve, generate meaningful evidence, and avoid preventable execution challenges. Integrating these capabilities can support a more deliberate, efficient, and scientifically grounded approach to women’s health development. 

Call to Action (CTA) 

Contact us to explore how Premier Research’s integrated scientific, regulatory, statistical, and clinical expertise can support your women’s health development strategy.  

Related Resources

Ready to Get Started? So Are We.

Connect With Us